UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

The New England journal of medicine, 2012-06, Vol.366 (26), p.2455-2465

2012

Volltextzugriff (PDF)

An immune-active tumor microenvironment favors clinical response to ipilimumab

Cancer Immunology, Immunotherapy, 2012-07, Vol.61 (7), p.1019-1031

2012

Volltextzugriff (PDF)

In vitro activation of rGM‐CSF derived bone marrow macrophages by cisplatin and lipopolysaccharide

Immunology and cell biology, 2017-12, Vol.69 (4), p.235-241

2017

Volltextzugriff (PDF)

Overexpression of manganese superoxide dismutase promotes survival in cell lines after doxorubicin treatment

British journal of haematology, 2003-02, Vol.120 (3), p.457-463

2003

Volltextzugriff (PDF)

Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab

Cancer Immunology, Immunotherapy, 2012-05, Vol.61 (5), p.733-737

2012

Volltextzugriff (PDF)

Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma

Cancer immunity, 2013, Vol.13, p.7

2013

Volltextzugriff (PDF)

Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.8022-8022

2014

Volltextzugriff (PDF)

First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.8024-8024

2014

Volltextzugriff (PDF)

Abstract 5513: An immune-active tumor microenvironment favors clinical response to ipilimumab

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.5513-5513

2011

Volltextzugriff (PDF)

Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.8113-8113

2014

Volltextzugriff (PDF)

A phase I study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus platinum-based doublet chemotherapy (PT-doublet) in chemotherapy-naive non-small cell lung cancer (NSCLC) patients (pts)

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.8072-8072

2013

Volltextzugriff (PDF)

Up-regulation of induction of lymphokine (IL-2)-activated killer (LAK) cell activity by FK-565 and cisplatin

Immunology letters, 1991-03, Vol.27 (3), p.199-204

1991

Volltextzugriff (PDF)

In vitro activation of rGM-CSF derived bone marrow macrophages by cisplatin and lipopolysaccharide

Immunology and cell biology, 1991-08, Vol.69, p.235-241

1991

Volltextzugriff (PDF)

Effect of interferon-gamma, tumor necrosis factor, interleukin-1 and interleukin-6 on the modulation of anti-tumor responses of bone marrow derived macrophages

International journal of immunopharmacology, 1993-04, Vol.15 (3), p.327-334

1993

Volltextzugriff (PDF)

In vitro activation of murine bone marrow-derived macrophages with cisplatin and mitomycin-C

International journal of immunopharmacology, 1991, Vol.13 (2), p.189-195

1991

Volltextzugriff (PDF)

Immunological and metabolic effects of prophylactic insulin therapy in the NOD-scid/scid adoptive transfer model of IDDM

Diabetes (New York, N.Y.), 1996-02, Vol.45 (2), p.205-208

1996

Volltextzugriff (PDF)

Production of interleukin-1 and tumor necrosis factor by bone marrow-derived macrophages: effect of cisplatin and lipopolysaccharide

Immunology letters, 1991-09, Vol.30 (1), p.93-100

1991

Volltextzugriff (PDF)

Meeting Highlights Anti-infectives: 96th General Meeting of the American Society for Microbiology New Orleans, Louisiana, USA, 19-23 May, 1996

Expert opinion on investigational drugs, 1996-07, Vol.5 (7), p.887-896

1996

Volltextzugriff (PDF)

Quantitation of resistance to cytosine arabinoside by myeloid leukemic cells expressing bcl-2

European journal of haematology, 1996-08, Vol.57 (2), p.149-156

1996

Volltextzugriff (PDF)

1 – 19 von 19

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(18)
Mit Volltextzugriff
(16)

Publikationsform

Artikel
(19)

Sprache

Englisch
(19)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

An immune-active tumor microenvironment favors clinical response to ipilimumab

In vitro activation of rGM‐CSF derived bone marrow macrophages by cisplatin and lipopolysaccharide

Overexpression of manganese superoxide dismutase promotes survival in cell lines after doxorubicin treatment

Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab

Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma

Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC

First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status

Abstract 5513: An immune-active tumor microenvironment favors clinical response to ipilimumab

Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC)

A phase I study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus platinum-based doublet chemotherapy (PT-doublet) in chemotherapy-naive non-small cell lung cancer (NSCLC) patients (pts)

Up-regulation of induction of lymphokine (IL-2)-activated killer (LAK) cell activity by FK-565 and cisplatin

In vitro activation of rGM-CSF derived bone marrow macrophages by cisplatin and lipopolysaccharide

Effect of interferon-gamma, tumor necrosis factor, interleukin-1 and interleukin-6 on the modulation of anti-tumor responses of bone marrow derived macrophages

In vitro activation of murine bone marrow-derived macrophages with cisplatin and mitomycin-C

Immunological and metabolic effects of prophylactic insulin therapy in the NOD-scid/scid adoptive transfer model of IDDM

Production of interleukin-1 and tumor necrosis factor by bone marrow-derived macrophages: effect of cisplatin and lipopolysaccharide

Meeting Highlights Anti-infectives: 96th General Meeting of the American Society for Microbiology New Orleans, Louisiana, USA, 19-23 May, 1996

Quantitation of resistance to cytosine arabinoside by myeloid leukemic cells expressing bcl-2

Suchergebnisse filtern